Clinical trials: Cytomegalovirus Infections
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Kidney Transplant Infection
Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.
Hypothesis: Valganciclovir prophylaxis can be discontinued before 3 months in CMV-seropositive renal transplant recipients receiving induction thymoglobulin when developing CMV-specific cellular immunity after transplantation.
- Trial name
- NCT03123627
- Testing
- New profilaxis, Profilaxis recommended
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cytomegalovirus Infections
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
- Trial name
- NCT04478474
- Testing
- Ganciclovir
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York Medical College
Cytomegalovirus Infections
Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease
OBJECTIVES: I. Evaluate the safety, tolerance, and potential efficacy of 3 doses of human anti-cytomegalovirus (CMV) monoclonal antibody SDZ MSL-109 (MOAB MSL-109) in the treatment of newborns with congenital CMV infection and no…
- Trial name
- NCT00004642
- Testing
- SDZ MSL-109
- Sponsor
- National Center for Research Resources (NCRR)
Foetuses Infection, Cytomegalovirus (CMV)Infection
In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir
The infection with cytomegalovirus (CMV) is the first cause of congenital neurological handicap of infectious origin. It is probable that the néonatale viral load is correlated with becoming of infected new-born babies.
- Trial name
- CYMEVAL2 (NCT01651585)
- Testing
- Valacyclovir arrow
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections, Gastrointestinal Diseases
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy.
- Trial name
- NCT00002145
- Testing
- Foscarnet sodium
- Where
- 15 sites in United States
- Volunteers
- 145 people
- Sponsor
- Astra USA
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
CMV Infection or Reactivation After Allogenic HSCT
CMV-TCR-T Cells for CM Virus Infection After HSCT
This is a single cente, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after HSCT.
- Trial name
- NCT04153279
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Disorder of Transplanted Kidney, Cytomegalovirus Infections
Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection
The aim of this the study is to the assess whether the graft and patient survival, rejection rates and renal graft function after the first year will not differ between both study arms.
- Trial name
- NCT01353053
- Where
- Brazil
- Volunteers
- 82 people
- Sponsor
- Federal University of São Paulo
Patients Undergoing Allogeneic Stem Cell Transplantation
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
In patients after allogeneic stem cell transplantation reactivation of latent herpesviruses such as Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) is a frequent and life threatening complication requiring antiviral treatment.
- Trial name
- NCT02227641
- Testing
- CMV/EBV specific T-cell
- Where
- 6 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Disorder of Cardiac Function
Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection
BACKGROUND Myocarditis and pericarditis are inflammatory conditions of the heart commonly due to viral or autoimmune etiologies. Human CMV represents one of the leading causes of congenital infections worldwide.
- Trial name
- NCT02787382
- Testing
- echocardiographic examination
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Cytomegalovirus Infections, HIV Infections
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study
To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate.
- Conditions
- Cytomegalovirus Infections, HIV Infections, Hypocalcemia
- Trial name
- NCT00002146
- Testing
- Magnesium sulfate, Foscarnet sodium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Astra USA
Cytomegalovirus Infections
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
The goal of STAGE I of the CMV TransmIT Study is to determine the prevalence of CMV shedding in children up to and including 36 months of age in large group childcare centers and in staff who regularly work at the center.
- Trial name
- NCT06522880
- Testing
- CMV PCR on saliva
- Where
- United States
- Sponsor
- University of Massachusetts, Worcester
Cytomegalovirus Infection
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV…
- Trial name
- NCT05683457
- Testing
- mRNA-1647
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- ModernaTX, Inc.
Hearing Loss, Cochlear, Cytomegalovirus Congenital
Cytomegalovirus (CMV) Perilymphatic Fluid
In France, children cochlear implantation (CI) is performed 400 times per year. Causes of profound sensorineural hearing loss (SNHL) are represented by congenital malformation of the inner ear for 50 to 60%.
- Trial name
- CMVP (NCT04724265)
- Testing
- collection of sample of perilymphatic fluid during cochlear implantation
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Infections, HIV Infections
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is…
- Trial name
- NCT00006145
- Testing
- Valganciclovir
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Double-stranded DNA Virus
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es).
- Trial name
- NCT01143181
- Testing
- Brincidofovir
- Where
- 37 sites in United States
- Volunteers
- 210 people
- Sponsor
- Jazz Pharmaceuticals
AdV Infection, EBV Infection
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality.
- Conditions
- AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
- Trial name
- TRACE (NCT04832607)
- Testing
- Multivirus (CMV, EBV, AdV)-specific T cells
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Tobias Feuchtinger
Heart Transplant Infection, Kidney Transplant Infection
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
CMV infection and disease remain a significant clinical challenge for pediatric solid organ transplant (SOT) recipients. Current prevention strategies are limited to prophylaxis in which antiviral medication is administered for a…
- Conditions
- Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
- Trial name
- NCT03924219
- Testing
- CMV T cell Immunity Assay
- Where
- 12 sites in United States
- Volunteers
- 161 people
- Sponsor
- Vanderbilt University Medical Center
To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT
To evaluate the efficacy and safety of secondary prophylaxis of CMV reactivation, clinically significant CMV infection with oral letermovir in Chinese haplo-HSCT patients, as well as treatment-related mortality, all-cause…
- Trial name
- NCT05914701
- Testing
- Letermovir for secondary prophylaxis
- Volunteers
- 31 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China